Back to search
FDAFDA · Food and drugs·Recall number D-0249-2019

Temozolomide capsules, 20 mg, packaged in a) 5-count bottle(NCD 43975-253-05), b) 14-count bottle (NDC 43975-253-14), Rx only, Mfd. by: Stason Pharmaceuticals, Inc., Irvine, CA 92618, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ 07071.

Published October 24, 2018 · Recall initiated: October 5, 2018

Summary

FDA records drug Class III recall D-0249-2019, published October 24, 2018 and initiated October 5, 2018. Recalling firm: Amerigen Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 5,232 bottles: a) 4,146 bottles; b) 1,086 bottles; Lot: Lot #: a) 17F058A, Exp 6/19; b) 17F058B, Exp 6/19. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed dissolution specifications: Out-of-Specification dissolution results obtained during stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Amerigen Pharmaceuticals Inc.
Distributor
Product was distributed U.S. nationwide.
Lot
Lot #: a) 17F058A, Exp 6/19; b) 17F058B, Exp 6/19
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Temozolomide capsules, 20 mg, packaged in a) 5-count bottle(NCD 43975-253-05), b) 14-count bottle (NDC 43975-253-14), Rx only, Mfd. by: Stason Pharmaceuticals, Inc., Irvine, CA 92618, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ 07071. recalled?

Yes. FDA published recall D-0249-2019 on October 24, 2018. Reported hazard: Failed dissolution specifications: Out-of-Specification dissolution results obtained during stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter